Castle Biosciences' 2026 Loss Estimate Narrows to $0.96 as Shares Rise 25.4%
Castle Biosciences holds a Zacks Rank #1 with 2026 loss-per-share estimates narrowing from $1.06 to $0.96 over the past 60 days. Its shares have risen 25.4% year over year, outperforming its biotech sector peers.
1. Analyst Rank and Outlook
Castle Biosciences holds a Zacks Rank #1, reflecting strong analyst confidence. Over the past 60 days, consensus 2026 loss-per-share estimates have narrowed from $1.06 to $0.96, while its shares have risen 25.4% over the past year, outperforming its biotech sector peers.
Related News
DAO
Youdao Q1 Revenue Rises 3.8% to RMB1.3B, Marketing Jumps 20.9%
DAO•
GOOG
OpenAI Eyes Fall IPO After Lawsuit Win, Battling $900B Anthropic Rival
GOOG•
RLAY
Relay Therapeutics Prices 22.9M Shares at $12 to Raise $275M
RLAY•
BBVA
BBVA Joins 25 Banks in 37-Member Qivalis Euro Stablecoin Consortium
BBVA•
GS
Oil Prices Rebound to $99–$106 After Trump Iran Deal Comments, Inventories Drop
GS•
Sources
F